
==== Front
ACS OmegaACS OmegaaoacsodfACS Omega2470-1343American Chemical Society 3145822610.1021/acsomega.8b02111ArticleSynthetic Access to Cyclopenta[a]inden-2(1H)-ones from Morita–Baylis–Hillman
Products of 2-Alkynyl Benzaldehydes Raji Reddy Chada *†§Warudikar Kamalkishor †§Sridhar Balasubramanian ‡§†Department
of Organic Synthesis & Process Chemistry and ‡Centre for X-Ray
Crystallography, CSIR—Indian Institute
of Chemical Technology, Hyderabad 500007, India§ Academy
of Scientific and Innovative Research (AcSIR), New Delhi 110020, India* E-mail: rajireddy@iict.res.in (C.R.R.).19 11 2018 30 11 2018 3 11 15734 15742 20 08 2018 07 11 2018 Copyright © 2018 American Chemical Society2018American Chemical SocietyThis is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

A new strategy for
the synthesis of cyclopenta[a]inden-2(1H)-ones has been developed. An intramolecular
Pauson–Khand reaction of the Morita–Baylis–Hillman
(MBH) adducts, derived from 2-alkynyl benzaldehydes, provided the
consequent novel cyclopenta[a]inden-2(1H)-ones bearing multifunctionalities including an ester group at the
fused ring junction (tert-carbon center). The generality
of this approach was illustrated by studying the several MBH derivatives
containing diverse substitutions/functionalities.

document-id-old-9ao8b02111document-id-new-14ao-2018-02111tccc-price
==== Body
Introduction
The Morita–Baylis–Hillman
(MBH) reaction has gained
renewed interest in organic synthesis as one of the atom-economical
carbon–carbon bond forming reactions.1 It provides the products having multifunctionalities which assist
as handy precursors to access various heterocycles and carbocycles.
Over the years, substantial efforts have been made for the utilization
of MBH adducts and their derivatives toward the synthesis of several
complex molecules including natural products and pharmaceuticals involving
various reactions.2 Despite these vast
applications, the employment of MBH-adducts in Pauson–Khand
reaction to access the cyclopentenones remains rare. For instance,
Kamimura reported the intramolecular Pauson–Khand reaction
of aza-Baylis–Hillman adducts (A) to obtain cis- and trans-pyrrolidine-fused cyclopentenones
(Scheme 1a).3a Our research group has demonstrated the sequential
allylic substitution/Pauson–Khand reaction to access bicyclic
fused cyclopentenones from MBH-acetates of acetylenic aldehydes (B, Scheme 1b).3b Our interest is on the enyne-assisted
annulations using MBH adducts;4 we envisaged
that the MBH adduct C, obtained from 2-alkynyl benzaldehyde,
would be a suitable substrate to the intramolecular Pauson–Khand
reaction generating the cyclopenta[a]inden-2(1H)-one (fused-cyclopentenone) having carboxylate functionality
at the fused ring junction (Scheme 1c). It is also noteworthy to mention that the chemistry
of MBH-adducts of 2-alkynyl benzaldehydes is less investigated.5

Scheme 1 a–c) Intramolecular Pauson–Khand
Reaction of MBH Derivatives
On the other hand, cyclopenta[a]indene
is an important
structural motif present in biologically significant natural products
as well as in pharmaceuticals (Figure 1).6 It also serves as a
key intermediate toward the synthesis of bio-active naturally occurring
molecules.7 Interestingly, to our knowledge,
there are presently few reports available for the synthesis of cyclopenta[a]inden-2(1H)-ones,8 precisely with substitution/functionality at the fused ring junction
(tert-carbon center).9 The Pauson–Khand
reaction, a carbonylative cyclization, is one of the commonly used
approaches to construct the cyclopentenones.10,11 However, the intramolecular Pauson–Khand reaction toward
the synthesis of tricyclic cyclopenta[a]inden-2(1H)-ones has been less exploited.12 Herein, we report the first direct access to cyclopenta[a]inden-2(1H)-one starting from readily
accessible MBH products of 2-alkynyl benzaldehydes involving the intramolecular
Pauson–Khand reaction as the key step.

Figure 1 Representative compounds
having cyclopenta[a]inden-2(1H)-one
skeleton.

Results and Discussion
To investigate
the envisaged Pauson–Khand reaction, we initially
selected Morita Baylis–Hillman adduct 5a (prepared
from the corresponding 2-alkynyl benzaldehyde) as the model substrate
and treated with Co2(CO)8 in 1,2-dichloroethane
(DCE) at 80 °C (Scheme 2). To our delight, the reaction progressed well to afford
the corresponding annulated product cyclopenta[a]inden-2(1H)-one, 6a in 64% yield as single diastereomer.
The stereochemistry of the major diastereomer was established as “cis”
(relation between hydroxyl and carboxylate group) by X-ray crystal
structure analysis (Figure 2, CCDC no. 1861746). The reaction scope was further extended
to MBH adduct 5b having n-propyl substitution on the
alkyne, which provided the cyclopenta[a]indenone 6b in 68% yield as single diastereomer (Scheme 2 & Figure 2, CCDC no. 1861745).

Figure 2 X-ray crystal structure of 6a and 6b (ellipsoids
are drawn at the 30% probability level.).

Scheme 2 Pauson–Khand Reaction of MBH Alcohol 5
Encouraged by this finding,
we studied the scope of amine-substituted
MBH adducts (Table 1), which were synthesized by allylic substitution of MBH carbonates
(prepared by tert-butyloxycarbonylation of MBH-alcohol 5). We employed the allylation of MBH carbonate 7a with
tosyl amine (TsNH2, 8a) in the presence of
5 mol % of 1,4-diazabicyclo[2.2.2]octane (DABCO) to give amino MBH
product 9a in 94% yield. Next, compound 9a was subjected to Pauson–Khand reaction using Co2(CO)8 in DCE at 80 °C and the formation of cyclopenta[a]indenone 10a was observed in 78% yield as
diastereomeric mixture (94:6). Other amino MBH substrates possessing
an aliphatic R group on the alkyne, such as n-propyl
(9b) and tert-butyloxy n-propyl (9c), also smoothly participated in the PK reaction
to provide the corresponding cyclopenta[a]indenones 10b and 10c in 72 and 68% yields, respectively,
with excellent diastereoselectivity (entry 2 and 3, Table 1). The cycloaddition reaction
of MBH derivative 9d with terminal alkyne was successful
to give the indenone 10d in 77% yield (entry 4). Afterward,
the chemoselectivity in Pauson–Khand reaction with respect
to two different olefins was verified through the reaction of N-allylamine derivative of MBH adduct 9e, obtained
by the treatment of 7a with N-allyl-4-methylbenzenesulfonamide
(8b). Gratifyingly, the reaction of 9e offered
exclusively the cyclopenta[a]indene-8a(1H)-carboxylate 10e in 82% yield with excellent diastereoselectivity
(entry 5, Table 1),
wherein highly substituted olefin underwent the cycloaddition with
alkyne favoring the formation of five-membered ring. Other substrates 9f and 9g also furnished the desired cyclopenta[a]indenones 10f and 10g in good
yield, albeit with lower diastereoselectivity (entry 6 & 7, Table 1). The PK reaction
of 9h gave the cyclopenta[a]indenone 10h in 81% yield with excellent diastereoselectivity (entry
8, Table 1). Further,
other aza-MBH substrates 9i with N-benzyl and 9j having tert-butylsilyloxy groups (prepared from the reaction of 7a with 8c and 8d, respectively)
were also well participated in the intramolecular Pauson–Khand
reaction to give the corresponding cyclopenta[a]indenones 10i and 10j with excellent diastereoselectivity
(entry 9 & 10, Table 1). The relative stereochemistry of the product 10e and 10j (CCDC nos. 1861747 and 1861744) was unequivocally
assigned by X-ray crystallography.

Table 1 Synthesis of Cyclopenta[a]indenones from Aza-MBH Derivatives
To further expand
the generality of the present method, the reactivity
of MBH adduct 11 generated from 2-alkynyl pyridine 3-carboxaldehyde,
was studied. Compound 11 was converted to the MBH carbonate 12 in 86% yield and subsequent substitution reaction of 12 with TsNH2 (8a) in the presence
of DABCO in toluene provided the aza-MBH substrate 13 in 79% yield. Satisfactorily, the intramolecular PK reaction of 13 was successful to obtain the desired pentaleno[1,2-b]pyridin-7(5H)-one 14 in
82% yield with excellent diastereoselectivity (Scheme 3).

Scheme 3 Synthesis of Pentaleno[1,2-b]pyridin-7(5H)-one
It was also possible to synthesize cyclopenta[a]inden-2(1H)-one 16 having
electron-withdrawing
group such as the cyano at the fused ring junction but in lower yield
along with the decyanated product 17 as single diastereomer
starting from the MBH adduct 15 (prepared from the reaction
of acrylonitrile with corresponding 2-alkynyl benzaldehyde, Scheme 4).5g The stereochemistry of the product 16 was
established as “cis” (relation between hydroxyl and
cyano group) by X-ray crystal structure analysis (CCDC no. 1871966).

Scheme 4 Pauson–Khand Reaction of MBH Alcohol 15 Having
CN Group
Conclusion
In
summary, we disclosed the novel synthetic utility of readily
accessible MBH adducts through the intramolecular Pauson–Khand
reaction. This method provides a facile access to new cyclopenta[a]inden-2(1H)-one scaffolds in high yield
and diastereoselectivity. A detailed study of substrate scope with
respect to the substitution at both benzylic position (hydroxyl and
diversely substituted amines) and alkyne functionality was done to
establish the practicality of the strategy. Further derivatization
of this cyclopenta[a]inden-2(1H)-ones
and evaluation of their biological properties are actively in progress.

General
Information
Unless otherwise noted, all reagents were used
as received from
commercial suppliers. All nonaqueous reactions were performed under
an atmosphere of nitrogen using oven-dried glassware and standard
syringe in septa techniques. All solvents were dried before use following
the standard procedures. Reactions were monitored using thin-layer
chromatography (SiO2). Thin-layer chromatography (TLC)
plates were visualized with UV light (254 nm), with iodine treatment,
or using ninhydrin, anisaldehyde stain. Column chromatography was
carried out using silica gel (100–200 mesh) packed in glass
columns. NMR spectra were recorded at 300, 400, 500 MHz (H) and at
75, 101, 126 MHz (C), respectively. Chemical shifts (δ) are
reported in ppm, using the residual solvent peak in CDCl3 (H: δ = 7.26 and C: δ = 77.16 ppm) as the internal standard,
and coupling constants (J) are given in Hz. Mass
spectra were obtained on VG 70–70H or LC/MSD trap SL spectrometer
operating at 70 eV using direct inlet system. High-resolution mass
spectra (HRMS) [ESI+] were obtained using either a TOF
or a double-focusing spectrometer. X-ray data for the compounds were
collected at room temperature using a Bruker Smart Apex CCD diffractometer
with graphite monochromated Mo Kα radiation (λ = 0.71073
Å) with ω-scan method. The diastereomeric ratio was calculated
based on the NMR spectra.

Experimental Section: Preparation of the
2-Alkynyl MBH Adducts
The 2-alkynyl benzaldehydes
were prepared by using 2-bromobenzaldehyde
with different terminal alkynes. The MBH adducts were prepared by
known literature procedure.5 Spectral data
are given below.

General Procedure for Synthesis of 5 and 11
A solution of 2-alkynylbenzaldehyde
(1.0 equiv),
methyl acrylate (3.0 equiv), and DABCO (1.0 equiv) was stirred in
a round-bottom flask at room temperature until completion of reaction
as monitored by TLC. Removal of solvent left crude reaction mixture,
which was separated by column chromatography (hexane/EtOAc) on silica
gel (100–200 mesh) to give the corresponding MBH adduct 5, was done. All new products were fully characterized.

Methyl 2-(Hydroxyl(2-(phenylethynyl)phenyl)methyl)acrylate
(5a)
Colorless liquid (2.5 g, 84%). 1H
NMR (500 MHz, CDCl3): δ 7.55 (dd, J = 16.9, 7.7 Hz, 2H), 7.49 (dd, J = 6.5, 3.1 Hz,
2H), 7.4–7.26 (m, 5H), 6.34 (s, 1H), 6.15 (d, J = 4.1 Hz, 1H), 5.68 (s, 1H), 3.75 (s, 3H), 3.26 (d, J = 4.8 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ
167.1, 142.6, 141.3, 132.2, 131.5, 128.7, 128.5, 128.4, 127.7, 126.9,
126.4, 123.0, 121.7, 94.6, 87.1, 70.8, 52.1. IR (KBr): νmax 3431, 2217, 1711, 1633, 1493, 1439 cm–1. MS (ESI): m/z 293 (M + H)+; HRMS (ESI): m/z calcd
for C19H17O3 (M + H)+,
293.1178; found, 293.1182.

Methyl 2-(Hydroxy(2-(pent-1-yn-1-yl)phenyl)methyl)acrylate
(5b)
Colorless liquid (1.27 g, 85%). 1H
NMR (400 MHz, CDCl3): δ 7.49–7.45 (m, 1H),
7.40 (dd, J = 7.6, 1.3 Hz, 1H), 7.30 (td, J = 7.6, 1.4 Hz, 1H), 7.22 (td, J = 7.5,
1.4 Hz, 1H), 6.32 (s, 1H), 6.04 (s, 1H), 5.62 (t, J = 1.2 Hz, 1H), 3.76 (s, 3H), 3.26 (s, 1H), 2.39 (t, J = 7.0 Hz, 2H), 1.67–1.56 (m, 2H), 1.06–0.99 (m, 3H). 13C NMR (101 MHz, CDCl3): δ 167.2, 142.3,
141.3, 132.3, 127.9, 127.5, 126.6, 126.3, 122.6, 95.8, 78.5, 70.7,
52.0, 22.1, 21.5, 13.5. IR (KBr): νmax 3480, 2961,
2931, 2872, 2233, 1718, 1630, 1438, 1380, 1260, 1191, 1141, 1029,
956, 936, 834, 752, 666, 609 cm–1. MS (ESI): m/z 281 (M + Na)+; HRMS (ESI): m/z calcd for C16H18O3Na (M + Na)+, 281.1154; found, 281.1158.

Methyl-2-((2-(5-((tert-butyldiphenylsilyl)oxy)pent-1-yn-yl)phenyl)(hydroxy)methyl)acrylate
(5c)
Yellow liquid (2.16 g, 72%). 1H NMR (400 MHz, CDCl3): δ 7.71–7.64 (m, 4H),
7.46 (d, J = 7.8 Hz, 1H), 7.43–7.34 (m, 6H),
7.32 (d, J = 11.2 Hz, 2H), 7.23–7.18 (m, 1H),
6.27 (d, J = 0.7 Hz, 1H), 5.99 (s, 1H), 5.61 (d, J = 1.2 Hz, 1H), 3.78 (t, J = 6.0 Hz, 2H),
3.70 (s, 3H), 3.14 (s, 1H), 2.58 (t, J = 7.1 Hz,
2H), 1.86–1.79 (m, 2H), 1.06 (s, 9H). 13C NMR (101
MHz, CDCl3): δ 167.1, 142.3, 141.2, 135.6, 133.8,
132.4, 129.6, 127.9, 127.7, 127.5, 126.6, 126.3, 122.5, 95.4, 78.5,
70.7, 62.4, 51.9, 31.6, 26.9, 19.3, 16.1. IR (KBr): νmax 3506, 3070, 2952, 2931, 2857, 1720, 1589, 1439, 1427, 1360, 1190,
1105, 1029, 985, 938, 821, 750, 700, 666, 612 cm–1. MS (ESI): m/z 535 (M + Na)+; HRMS (ESI): m/z calcd
for C32H36O4SiNa (M + Na)+, 535.2282; found, 535.2281.

Methyl 2-((2-Ethynylphenyl)(hydroxyl)methyl)acrylate
(5d)
Colorless liquid (800 mg, 79%). 1H
NMR (500 MHz, CDCl3): δ 7.54–7.48 (m, 2H),
7.39 (td, J = 7.7, 1.3 Hz, 1H), 7.27 (ddd, J = 7.5, 6.7, 1.2 Hz, 1H), 6.34 (s, 1H), 6.07 (s, 1H), 5.66
(t, J = 1.1 Hz, 1H), 3.76 (s, 3H), 3.30 (s, 1H). 13C NMR (101 MHz, CDCl3): δ 167, 143.1, 141.1,
132.9, 129.2, 127.7, 126.8, 126.5, 120.8, 82.3, 81.4, 70.5, 52.1.
νmax 3435, 3280, 2104, 1715, 1629, 1435 cm–1. MS (ESI): m/z 239 (M + Na)+; HRMS (ESI): m/z calcd
for C13H12NaO3Na (M + Na)+, 239.0679; found, 239.0671.

General Procedure for the
Preparation of MBH-Carbonates (7a–7d and 12)
To a stirred solution of the corresponding
MBH-alcohol (5) (1 equiv) in 10 mL of CH2Cl2 was added ditert-butyl dicarbonate (1.2
equiv) and DMAP (0.05 equiv)
at 0 °C and stirred up to completion then, the mixture was diluted
with water (50 mL) and extracted with CH2Cl2 (3 × 30 mL). The combined organic layer was dried over anhydrous
Na2SO4 and concentrated in vacuo. The crude
was purified by column chromatography on silica gel (EtOAc/hexane)
to afford the corresponding MBH-carbonate. All these carbonates were
fully characterized and spectral data are given below.

Methyl 2-(((tert-Butoxycarbonyl)oxy)(2-(phenylethynyl)phenyl)methyl)acrylate
(7a)
White solid (3.68 g, 91%). mp 80–83
°C. 1H NMR (500 MHz, CDCl3): δ 7.55
(dt, J = 5.2, 4.4 Hz, 3H), 7.43–7.39 (m, 1H),
7.36–7.28 (m, 5H), 7.08 (s, 1H), 6.49 (s, 1H), 5.74 (s, 1H),
3.71 (s, 3H), 1.44 (s, 9H). 13C NMR (101 MHz, CDCl3): δ 165.6, 152.3, 139.1, 138.8, 132.4, 131.7 (2C),
128.4, 128.3 (2C), 127.9, 126.6, 123.1, 122.9, 94.9, 86.6, 82.7, 73.9,
52.1, 27.9. IR (KBr): νmax 2982, 1744, 1600, 1477,
1370, 1249, 1117, 961, 845, 749, 666 cm–1. MS (ESI): m/z 415 (M + Na)+; HRMS (ESI): m/z calcd for C24H24NaO5Na (M + Na)+, 415.1516; found, 415.1552.

Methyl 2-(((tert-Butoxycarbonyl)oxy)(2-(pent-1-yn-1-yl)phenyl)methyl)acrylate
(7b)
Colorless liquid (1.19 g, 86%). 1H NMR (300 MHz, CDCl3): δ 7.45–7.39 (m, 1H),
7.37–7.33 (m, 1H), 7.31–7.21 (m, 2H), 6.96 (s, 1H),
6.45 (s, 1H), 5.62 (s, 1H), 3.75 (s, 3H), 2.39 (t, J = 7.0 Hz, 2H), 1.60 (dd, J = 8.5, 5.9 Hz, 2H),
1.47 (s, 9H), 1.02 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 165.6, 152.4, 138.9, 138.8,
132.3, 128.1, 127.8, 127.6, 126.4, 123.6, 96.1, 82.4, 77.9, 73.9,
52.0, 27.7, 22.1, 21.6, 13.6. IR (KBr): νmax 2956,
2854, 1746, 1729, 1369, 1248, 1154, 961, 870, 756, 701, 613 cm–1. MS (ESI): m/z 381
(M + Na)+; HRMS (ESI): m/z calcd for C21H26 O5Na (M + Na)+, 381.1678; found, 381.1680.

Methyl-2-(((tert-butoxycarbonyl)oxy)(2-(5-((tert-butyldiphenylsilyl)oxy)pent-1-yn-1-yl)phenyl)methyl)acrylate
(7c)
Brown liquid (1.93 g, 75%). 1H NMR (400 MHz, CDCl3): δ 7.70–7.64 (m, 4H),
7.43–7.32 (m, 8H), 7.30–7.20 (m, 2H), 6.94 (s, 1H),
6.40 (s, 1H), 5.62 (dd, J = 3.6, 2.6 Hz, 1H), 3.81–3.74
(m, 2H), 3.70–3.64 (s, 3H), 2.57 (t, J = 7.2
Hz, 2H), 1.84 (pd, J = 7.6, 3.7 Hz, 2H), 1.45 (s,
9H), 1.09–1.02 (m, 9H). 13C NMR (101 MHz, CDCl3): δ 165.6, 152.4, 138.9, 138.8, 135.6, 133.9, 132.4,
129.6, 128.1, 127.9, 127.7, 126.4, 123.6, 95.8, 82.5, 77.9, 73.9,
62.6, 52.0, 31.7, 27.8, 26.9, 19.3, 16.2. IR (KBr): νmax 2931, 2857, 1748, 1429, 1275, 1109, 962, 704. MS (ESI): m/z 635 (M + Na)+; HRMS (ESI): m/z calcd for C37H44O6SiNa (M + Na)+, 635.2799; found, 635.2820.

Methyl 2-(((tert-Butoxycarbonyl)oxy)(2-ethynylphenyl)methyl)acrylate
(7d)
Colorless liquid (1.02 g, 88%). 1H NMR (500 MHz, CDCl3): δ 7.52 (dd, J = 7.6, 1.0 Hz, 1H), 7.40–7.33 (m, 2H), 7.31–7.26 (m,
1H), 6.96 (s, 1H), 6.46 (s, 1H), 5.71–5.65 (s, 1H), 3.74 (s,
3H), 3.32 (s, 1H), 1.47 (s, 9H). 13C NMR (126 MHz, CDCl3): δ 165.4, 152.3, 139.7, 138.6, 133.1, 129.1, 128.2,
127.8, 126.8, 121.8, 82.6, 82.6, 80.7, 73.7, 52.1, 27.7. IR (KBr):
νmax 3302, 2982, 1727, 1370, 1251, 1153, 962, 845,
748, 666 cm–1. MS (ESI): m/z 339 (M + Na)+; HRMS (ESI): m/z calcd for C18H21O5 (M + H)+, 317.1384; found, 317.1367.

General Procedure
for the Synthesis of Intermediate (9a–9j and 13)
To a stirred solution of the corresponding
MBH-carbonate 7 (1 equiv) in 2 mL of toluene was added
amine 8 (0.8 equiv) and DABCO (0.05 equiv) at 0 °C
and stirred up to completion. Then, the removal of solvent left crude,
which was purified by column chromatography on silica gel (100–200
mesh), (EtOAc/hexane) to afford the corresponding aminated MBH adduct 9. All these compounds were fully characterized by obtaining
spectral data.

Methyl-2-(((4-methylphenyl)sulfonamido)(2-(phenylethynyl)phenyl)methyl)acrylate
(9a)
Yellow liquid (106 mg, 94%). 1H NMR (400 MHz, CDCl3): δ 7.62 (d, J = 8.3 Hz, 2H), 7.51 (dq, J = 7.6, 2.4 Hz, 2H),
7.43–7.36 (m, 4H), 7.33–7.28 (m, 1H), 7.20–7.15
(m, 2H), 7.07 (d, J = 8.1 Hz, 2H), 6.24 (s, 1H),
5.89 (d, J = 14.6 Hz, 3H), 3.61 (s, 3H), 2.29 (s,
3H). 13C NMR (126 MHz, CDCl3): δ 165.9,
143.1, 139.8, 138.6, 137.3, 132.6, 131.6, 129.3, 128.7, 128.5 (2C),
128.1, 127.5, 127.4, 127.2, 122.8, 121.7, 95.2, 87.2, 56.9, 52.0,
21.4. IR (KBr): νmax 3277, 2951, 2923, 1721, 1598,
1329, 1193, 1155, 1060, 915, 811, 753, 664 cm–1.
MS (ESI): m/z (M + Na)+ 468.30; HRMS (ESI): m/z calcd
for C26H24NO4S (M + H)+, 446.1421; found, 446.1430.

Methyl 2-(((4-Methylphenyl)sulfonamido)(2-(pent-1-yn-1-yl)phenyl)methyl)acrylate
(9b)
Pale yellow solid (99 mg, 87%). mp 90–92
°C. 1H NMR (500 MHz, CDCl3): δ 7.59
(d, J = 8.3 Hz, 2H), 7.28–7.26 (m, 1H), 7.19
(dd, J = 7.2, 1.8 Hz, 1H), 7.13–7.05 (m, 4H),
6.21 (s, 1H), 5.94 (d, J = 9.3 Hz, 1H), 5.85–5.74
(m, 2H), 3.63 (s, 3H), 2.40 (t, J = 7.1 Hz, 2H),
2.34 (s, 3H), 1.69–1.59 (m, 2H), 1.06 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ
166, 143, 139.2, 138.4, 137.6, 132.8, 129.2, 127.7, 127.6, 127.5,
127.3, 127.1, 122.4, 96.7, 78.7, 57.2, 51.9, 22.1, 21.6, 21.4, 13.7.
IR (KBr): νmax 3282, 3020, 2872, 2232, 1724, 1483,
1214, 1159, 1063, 918, 813, 753, 667 cm–1. MS (ESI): m/z 434 (M + Na)+; HRMS (ESI): m/z calcd for C23H25NO4SNa (M + Na)+, 434.1402; found, 434.1402.

Methyl-2-((2-(5-((tert-butyldiphenylsilyl)oxy)pent-1-yn-1-yl)phenyl)(4-methylphenyl
sulfonamido) methyl)acrylate (9c)
Pale yellow
solid (89 mg, 82%). mp 85–87 °C. 1H NMR (400
MHz, CDCl3): δ 7.68 (dt, J = 7.5,
3.7 Hz, 4H), 7.57 (d, J = 8.3 Hz, 2H), 7.43–7.34
(m, 6H), 7.24–7.16 (m, 2H), 7.08 (ddd, J =
6.4, 4.8, 3.0 Hz, 4H), 6.17 (s, 1H), 5.81 (s, 1H), 5.81–5.73
(m, 2H), 3.79 (t, J = 5.9 Hz, 2H), 3.60 (s, 3H),
2.58 (t, J = 7.3 Hz, 2H), 2.31 (s, 3H), 1.89–1.82
(m, 2H), 1.07 (s, 9H). 13C NMR (126 MHz, CDCl3): δ 166, 143, 139.2, 138.3, 137.6, 135.6, 133.8, 132.9, 129.6,
129.2, 127.7, 127.7, 127.6, 127.4, 127.3, 127.1, 122.3, 96.4, 78.7,
62.5, 57.3, 51.9, 31.6, 26.9, 21.4, 19.3, 16.2. IR (KBr): νmax 2931, 1726, 1428, 1332, 1262, 1157, 1109, 704. MS (ESI): m/z 688 (M + Na)+; HRMS (ESI): m/z calcd for C39H43NNaO5SSi (M + Na)+, 688.2523; found, 688.2546.

Methyl 2-((2-Ethynylphenyl)(4-methylphenylsulfonamido)methyl)acrylate
(9d)
White solid (92 mg, 79%). mp 143–145
°C. 1H NMR (400 MHz, CDCl3): δ 7.65–7.60
(m, 2H), 7.37 (dd, J = 7.4, 1.6 Hz, 1H), 7.26 (dd, J = 7.8, 1.4 Hz, 1H), 7.22–7.10 (m, 4H), 6.26 (s,
1H), 5.93 (s, 1H), 5.84 (d, J = 19.2 Hz, 1H), 5.81
(d, J = 8.9 Hz, 1H), 3.63 (s, 3H), 3.27 (s, 1H),
2.35 (s, 3H). 13C NMR (101 MHz, CDCl3): δ
165, 142.1, 139.2, 136.9, 136.4, 132.3, 128.2, 127.9, 127.2, 126.4,
126.4, 126.2, 119.6, 82.2, 80.3, 56, 51, 20.4. IR (KBr): νmax 2958, 2858, 1730, 1554, 1365, 1257, 1172, 759. MS (ESI): m/z 392 (M + Na)+; HRMS (ESI): m/z calcd for C20H19NO4SNa (M + Na)+, 392.0927; found, 392.0932.

Methyl 2-(((N-Allyl-4-methylphenyl)sulfonamido)(2-(phenylethynyl)phenyl)methyl)acrylate
(9e)
Pale yellow liquid (117 mg, 95%).1H NMR (500 MHz, CDCl3): δ 7.54 (d, J = 8.3 Hz, 2H), 7.46–7.43 (m, 2H), 7.42–7.38 (m, 1H),
7.30–7.24 (m, 4H), 7.20–7.15 (m, 2H), 7.05 (d, J = 8.1 Hz, 2H), 6.53 (s, 1H), 6.43 (s, 1H), 5.53 (d, J = 1.0 Hz, 1H), 5.48–5.36 (m, 1H), 4.85–4.75
(m, 2H), 3.95 (d, J = 6.3 Hz, 2H), 3.45 (s, 3H),
2.29 (s, 3H). 13C NMR (126 MHz, CDCl3): δ
166.1, 142.8, 140.1, 139, 138.1, 134.2, 132.7, 131.7, 130.3, 129.1,
128.4, 128.3, 128.3, 128.2, 127.8, 127.6, 123.1, 123.1, 117.5, 95.2,
87.3, 60.6, 51.9, 50.3, 21.3. IR (KBr): νmax 3021,
2951, 1721, 1598, 1493, 1339, 1156, 1089, 928, 811, 747, 665 cm–1. MS (ESI): m/z 508
(M + Na)+; HRMS (ESI): m/z calcd for C29H27NO4SNa (M + Na)+, 508.1553; found, 508.1537.

Methyl 2-(((N-Allyl-4-methylphenyl)sulfonamido)(2-(pent-1-yn-1-yl)phenyl)methyl)acrylate
(9f)
Colorless liquid (112 mg, 89%).1H NMR (400 MHz, CDCl3): δ 7.51 (d, J = 8.3 Hz, 2H), 7.30–7.19 (m, 1H), 7.21–7.14 (m, 1H),
7.13–7.05 (m, 4H), 6.40 (d, J = 11.7 Hz, 2H),
5.50–5.38 (m, 2H), 4.85–4.77 (m, 2H), 3.91 (d, J = 6.3 Hz, 2H), 3.50 (s, 3H), 2.33–2.28 (m, 5H),
1.52 (dd, J = 14.4, 7.2 Hz, 2H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ 166.1, 142.8, 139.7, 139.1, 138.1, 134.4, 132.6, 129.9,
129.1, 128.1, 127.7, 127.4, 127.3, 124.1, 117.4, 96.6, 78.5, 60.5,
51.8, 50.3, 22.1, 21.7, 21.5, 13.6. IR (KBr): νmax 3021, 2925, 2853, 2234, 1724, 1598, 1341, 1158, 1090, 929, 755,
666 cm–1. MS (ESI): m/z 474 (M + Na)+; HRMS (ESI): m/z calcd for C26H29NO4SNa
(M + Na)+, 474.1715; found, 474.1711.

Methyl 2-(((N-Allyl-4-methylphenyl)sulfonamido)(2-(5-((tert-butyldiphenylsilyl)oxy)pent-1-yn-1-yl)phenyl)methyl)acrylate
(9g)
Colorless liquid (89 mg, 78%). 1H NMR (400 MHz, CDCl3): δ 7.67 (d, J = 6.4 Hz, 4H), 7.57 (d, J = 8.3 Hz, 2H), 7.43–7.33
(m, 6H), 7.29 (dd, J = 6.1, 3.0 Hz, 1H), 7.25–7.22
(m, 1H), 7.19–7.12 (m, 4H), 6.46 (s, 1H), 6.41 (s, 1H), 5.49
(dd, J = 10.8, 6.2 Hz, 2H), 4.90–4.80 (m,
2H), 3.96 (d, J = 6.3 Hz, 2H), 3.75 (t, J = 6.0 Hz, 2H), 3.51 (s, 3H), 2.55 (q, J = 7.5 Hz,
2H), 2.35 (s, 3H), 1.82 (dd, J = 13.7, 6.8 Hz, 2H),
1.05 (s, 9H). 13C NMR (101 MHz, CDCl3): δ
166.1, 142.8, 139.7, 139.1, 138.1, 135.6, 134.4, 133.8, 132.6, 129.9,
129.6, 129.1, 128.1, 127.7, 127.4, 124.1, 117.5, 96.3, 78.6, 62.6,
60.5, 51.9, 50.3, 31.5, 26.9, 21.5, 19.3, 16.3. IR (KBr): νmax 3070, 2930, 1723, 1598, 1428, 1342, 1260, 1156, 1090, 935,
811, 700, 660 cm–1. MS (ESI): m/z 728 (M + Na)+; HRMS (ESI): m/z calcd for C42H47NO5SSiNa (M + Na)+, 728.2836; found, 728.2871.

Methyl 2-(((N-Allyl-4-methylphenyl)sulfonamido)(2-ethynylphenyl)methyl)acrylate
(9h)
White solid (115 mg, 89%). mp 90–92
°C. 1H NMR (500 MHz, CDCl3): δ 7.61–7.56
(m, 2H), 7.41 (dd, J = 7.5, 1.4 Hz, 1H), 7.33–7.30
(m, 1H), 7.29–7.19 (m, 2H), 7.17 (d, J = 8.0
Hz, 2H), 6.50 (s, 1H), 6.46 (s, 1H), 5.62 (d, J =
1.2 Hz, 1H), 5.50 (ddt, J = 16.5, 10.2, 6.3 Hz, 1H),
4.93–4.83 (m, 2H), 4.02–3.99 (m, 2H), 3.59 (s, 3H),
3.25 (s, 1H), 2.39 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 166.1, 142.9, 140.4, 139.1, 138, 134.3, 133.3,
129.9, 129.1, 128.7, 128.4, 127.7, 127.6, 122.2, 117.6, 83.2, 81.3,
60.4, 52.1, 50.4, 21.5. IR (KBr): νmax 3300, 3023,
1720, 1439, 1337, 1214, 1153, 1033, 933, 743, 663 cm–1. MS (ESI): m/z 432 (M + Na)+; HRMS (ESI): m/z calcd
for C23H23NO4SNa (M + Na)+, 432.1240; found, 432.1280.

Methyl-2-((N-((tert-butyldimethylsilyl)oxy)-4-methylphenylsulfonamido)(2(phenylethynyl)-phenyl)methyl)acrylate
(9i)
White solid (124 mg, 85%); mp 152–154
°C; 1H NMR (500 MHz, CDCl3): δ 7.75–7.64
(m, 3H), 7.48 (s, 3H), 7.35 (s, 3H), 7.23–7.16 (m, 2H), 7.06
(d, J = 7.1 Hz, 2H), 6.59 (s, 1H), 6.33 (s, 1H),
5.25 (s, 1H), 3.47 (s, 3H), 2.32 (s, 3H), 0.95 (s, 9H), 0.36 (s, 3H),
0.17 (s, 3H). 13C NMR (101 MHz, CDCl3): δ
166.3, 143, 139.7, 137.9, 132.4, 132.1, 131.8, 131.2, 130.2, 129.2,
128.9, 128.4, 128.2, 127.9, 127.2, 123.1, 122.4, 94.8, 86.9, 63.1,
51.8, 26.4, 21.5, 18.6, −3.6, −3.7. IR (KBr): νmax 2958, 2858, 1913, 1730, 1365, 1172, 812 cm–1. MS (ESI): m/z 598 (M + Na)+; HRMS (ESI): m/z calcd
for C32H37NO5SSiNa (M + Na)+, 598.2065; found, 598.2059.

Methyl-2-((N-benzyl-4-methylphenylsulfonamido)(2-(phenylethynyl)phenyl)methyl)acrylate
(9j)
Colorless liquid (129 mg, 95%). 1H NMR (400 MHz, CDCl3): δ 7.54–7.45 (m, 4H),
7.38–7.29 (m, 5H), 7.18–7.13 (m, 4H), 7.13–7.05
(m, 5H).6.54 (s, 1H), 6.36 (s, 1H), 5.55 (d, J =
0.9 Hz, 1H), 4.71 (s, 2H), 3.42 (s, 3H), 2.34 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 166, 142.8, 140.1, 138.5,
138.1, 136.7, 132.4, 131.6, 131.1, 129.1, 128.6, 128.5, 128.4, 128.4,
128.1, 128.1, 127.6, 127.3, 127.2, 123.1, 122.9, 95.1, 87.4, 61.1,
52.6, 51.7. IR (KBr): νmax 3062, 3027, 2949, 1721,
1598, 1493, 1339, 1155, 1029, 925, 811, 754, 666 cm–1. MS (ESI): m/z 558 (M + Na)+; HRMS (ESI): m/z calcd
for C33H29NO4SNa (M + Na)+, 558.1715; found, 558.1718.

General Experimental Procedure
for Pauson–Khand Reaction
(6a, 6b, 10a–10j and 14)
To a stirred solution of compound 5 or 9 or 13 (1 equiv) in DCE (5 mL) at
room temperature was added Co2(CO)8 (1.1 equiv),
and the mixture was stirred at room temperature until the consumption
of the Co2(CO)8–eneyne complex (monitored
by TLC, 2 h). Then, it was heated to 80 °C till completion (monitored
by TLC). The reaction mixture was filtered through a Celite pad, and
solvent was evaporated to get crude reaction mixture, which was purified
by silica gel (100–200 mesh) column chromatography to obtain
the corresponding cyclopenta[a]inden-2(1H)-one 6 or 10 or 14.

Methyl 8-Hydroxy-2-oxo-3-phenyl-1,2,8,8a-tetrahydrocyclopenta[a]indene-8a-carboxylate (6a)
Pale
yellow solid (69 mg, 64%); mp 147–149 °C; 1H NMR (400 MHz, CDCl3): δ 7.69 (d, J = 7.7 Hz, 1H), 7.58 (d, J = 7.6 Hz, 1H), 7.51–7.32
(m, 6H), 7.26 (t, J = 7.6 Hz, 1H), 5.43 (d, J = 5.3 Hz, 1H), 3.55 (s, 3H), 3.06 (d, J = 17.0 Hz, 1H), 2.89 (d, J = 17.0 Hz, 1H), 1.85
(d, J = 6.2 Hz, 1H). 13C NMR (101 MHz,
CDCl3): δ 204.9, 171.7, 168.6, 148.1, 136.5, 132.9,
131.74, 129.5, 128.9, 128.4, 127.9, 127.4, 125.5, 123.6, 72.1, 64,
52.1, 41.1. IR (KBr): νmax 3450. 3017, 1708, 1348,
1244, 1021, 757. MS (ESI): m/z 343
(M + Na)+; HRMS (ESI): m/z calcd for C20H16O4Na (M + H)+, 343.0941; found, 343.0944.

Methyl 8-Hydroxy-2-oxo-3-propyl-1,2,8,8a-tetrahydrocyclopenta[a]indene-8a-carboxylate (6b)
White
solid, (75 mg, 68%); mp 117–119 °C; 1H NMR
(300 MHz, CDCl3): δ 7.57 (dt, J =
16.7, 7.5 Hz, 3H), 7.41 (t, J = 7.5 Hz, 1H), 5.06
(d, J = 12.0 Hz, 1H), 4.45 (d, J = 11.9 Hz, 1H), 3.63 (s, 3H), 3.10 (d, J = 17.3
Hz, 1H), 2.70 (d, J = 17.2 Hz, 1H), 2.44 (dtd, J = 20.6, 13.4, 7.5 Hz, 2H), 1.59 (dd, J = 14.0, 7.1 Hz, 2H), 0.93 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 207.3, 174.0,
167.3, 149.2, 136.1, 132.5, 131.9, 128.9, 124.2 (2C), 80.3, 66.2,
53.1, 45.1, 25.5, 21.7, 13.8. IR (KBr): νmax 3479,
3019, 2922, 2852, 1708, 1435, 1214, 784. MS (ESI): m/z 309 (M + Na)+; HRMS (ESI): m/z calcd for C17H18O4Na (M + Na)+, 309.1112; found, 309.1103.

Methyl 8-((4-Methylphenyl)sulfonamido)-2-oxo-3-phenyl-2,8-dihydrocyclopenta[a]indene-8a(1H)-arboxylate (10a)
Pale yellow solid (87 mg, 78%); mp 190–192 °C; 1H NMR (400 MHz, CDCl3): δ 7.83 (d, J = 8.3 Hz, 2H), 7.61 (d, J = 7.7 Hz, 1H),
7.50–7.39 (m, 7H), 7.36 (d, J = 8.0 Hz, 2H),
7.28–7.22 (m, 1H).6.49 (d, J = 10.6 Hz, 1H),
4.92 (d, J = 10.6 Hz, 1H), 3.61 (s, 3H), 2.66 (d, J = 17.2 Hz, 1H), 2.52–2.45 (m, 4H). 13C NMR (101 MHz, CDCl3): δ 204.8, 172.3, 167.5, 146.7,
144.2, 137.9, 135.0, 132.9, 132.1, 130.0, 129.9, 129.2, 129.0, 128.9,
128.4, 127.1, 124.3, 124.1, 65.9, 62.7, 53.4, 45.7, 21.7. IR (KBr):
νmax 3274, 2922, 1705, 1433, 1157, 1081, 747, 663
cm–1. MS (ESI): m/z 496 (M + Na)+; HRMS (ESI): m/z calcd for C27H24NO5S
(M + H)+, 474.1370; found, 474.1355.

Methyl 8-((4-Methylphenyl)sulfonamido)-2-oxo-3-propyl-2,8-dihydrocyclopenta[a]indene-8a(1H)-carboxylate (10b)
White solid (76 mg, 72%); mp 148–150 °C; 1H NMR (400 MHz, CDCl3): δ 7.80 (d, J = 8.1 Hz, 2H), 7.55–7.31 (m, 6H), 6.50 (d, J = 10.6 Hz, 1H), 4.80 (d, J = 10.6 Hz,
1H), 3.55 (s, 3H), 2.51–2.39 (m, 5H), 2.35–2.21 (m,
2H), 1.48 (s, 2H), 0.91 (dt, J = 14.7, 7.3 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 206.7, 172.5,
167.3, 146.3, 144.0, 137.9, 136.4, 132.5, 132.0 (2C), 129.9, 129.1,
127.1, 124.4, 124.3, 65.8, 62.7, 53.1, 45.2, 27.9, 25.4, 21.6, 13.7.
IR (KBr): νmax 3292, 3020, 2959, 2932, 2871, 1707,
1649, 1598, 1493, 1215, 1161, 930, 815, 753, 664 cm–1. MS (ESI): m/z 440 (M + H)+; HRMS (ESI): m/z calcd
for C24H26NO5S (M + H)+, 440.1526; found, 440.1528.

Methyl 3-(3-((tert-Butyldiphenylsilyl)oxy)propyl)-8-((4-methylphenyl)sulfonamido)-2-oxo-2,8-dihydro-cyclopenta[a]indene-8a(1H)-carboxylate (10c)
White solid (63 mg, 68%); mp 145–147 °C; 1H NMR (400 MHz, CDCl3): δ 7.80 (d, J = 8.3 Hz, 2H), 7.65–7.60 (m, 5H), 7.47–7.38
(m, 4H), 7.37–7.32 (m, 6H), 7.27–7.25 (m, 1H), 6.48
(d, J = 10.6 Hz, 1H), 4.78 (d, J = 10.6 Hz, 1H), 3.64 (t, J = 5.9 Hz, 2H), 3.50
(s, 3H), 2.56 (dd, J = 11.3, 4.7 Hz, 2H), 2.47–2.39
(m, 4H), 2.22 (d, J = 17.2 Hz, 1H), 1.78–1.62
(m, 2H), 1.06 (s, 9H). 13C NMR (126 MHz, CDCl3): δ 206.6, 172.5, 167.5, 146.2, 144.1, 137.9, 136.1, 135.5,
135.5, 133.7, 133.7, 132.4, 132.1, 129.9, 129.7, 129.1, 127.7, 127.1,
124.8, 124.2, 65.8, 63.1, 62.7, 53.1, 45.3, 31.1, 26.9, 21.7, 20.1,
19.3. IR (KBr): νmax 3295, 2955, 2924, 2854, 1708,
1650, 1599, 1427, 1339, 1215, 1091, 1028, 934, 815, 752, 663 cm–1. MS (ESI): m/z 716
(M + Na)+; HRMS (ESI): m/z calcd for C40H43NO6SSiNa (M + Na)+, 716.2473; found, 716.2508.

Methyl 8-(4-Methylphenylsulfonamido)-2-oxo-1,2,8,8a-tetrahydrocyclopenta[a]indene-8a-carboxylate (10d)
Pale
yellow solid (76 mg, 77%); mp 199–201 °C; 1H NMR (400 MHz, CDCl3): δ 7.75–7.71 (m, 2H),
7.44 (ddd, J = 8.7, 5.4, 1.7 Hz, 2H), 7.37–7.30
(m, 2H), 7.27 (d, J = 7.9 Hz, 2H), 6.40 (d, J = 10.7 Hz, 1H), 6.13 (s, 1H), 4.77 (d, J = 10.7 Hz, 1H), 3.51 (s, 3H), 2.42–2.36 (m, 4H), 2.25 (d, J = 17.1 Hz, 1H). 13C NMR (101 MHz, CDCl3): δ 206.5, 174.9, 171.8, 146.5, 144.1, 137.8, 133.1,
131.8, 129.9, 129.3, 127.1, 124.4, 124.3, 122.2, 67.8, 62.6, 53.3,
46.2, 21.7. IR (KBr): νmax 3019, 2955, 1708, 1625,
1434, 1215, 1160, 1029, 896, 814, 743, 661 cm–1.
MS (ESI): m/z 398 (M + H)+; HRMS (ESI): m/z calcd for C21H19NO5SNa (M + Na)+, 420.0882;
found, 420.0873.

Methyl 8-((N-Allyl-4-methylphenyl)sulfonamido)-2-oxo-3-phenyl-2,8-dihydrocyclopenta[a]indene-8a(1H)-carboxylate (10e)
White solid (101 mg, 82%); mp 142–144 °C; 1H NMR (500 MHz, CDCl3): δ 7.80 (d, J = 8.3 Hz, 2H), 7.70 (d, J = 7.7 Hz, 1H),
7.50–7.44 (m, 4H), 7.40 (ddd, J = 6.4, 3.8,
1.8 Hz, 1H), 7.33 (dd, J = 9.7, 7.5 Hz, 3H), 7.25–7.20
(m, 1H), 6.76 (d, J = 7.6 Hz, 1H), 5.84 (ddd, J = 15.3, 10.1, 4.9 Hz, 1H), 5.72 (s, 1H), 5.13 (ddd, J = 13.8, 11.5, 1.2 Hz, 2H), 3.90 (d, J = 5.7 Hz, 2H), 3.60 (s, 3H), 3.51 (d, J = 17.6
Hz, 1H), 2.95 (d, J = 17.7 Hz, 1H), 2.46 (s, 3H); 13C NMR (101 MHz, CDCl3): δ 204.6, 170.9,
168.1, 144.1, 142.8, 135.7, 129.8, 129.7, 128.9, 128.9, 128.4, 127.7,
116.8, 77.4, 77.1, 76.8, 70.2, 65.9, 53.2, 48.9, 46.3, 21.6. IR (KBr):
νmax 1704, 1343, 1156, 1089, 1024, 921, 735, 661
cm–1. MS (ESI): m/z 536 (M + Na)+; HRMS (ESI): m/z calcd for C30H27NO5SNa
(M + Na)+, 536.1502; found, 536.1493.

Methyl 8-(N-Allyl-4-methylphenylsulfonamido)-2-oxo-3-propyl-1,2,8,8a-tetrahydrocyclopenta[a]indene-8a-carboxylate (10f)
White
solid (92 mg, 78%); mp 138–140 °C; 1H NMR (500
MHz, CDCl3): δ 7.84 (d, J = 8.1
Hz, 2H), 7.62 (t, J = 8.4 Hz, 1H), 7.46–7.29
(m, 4H), 7.01 (d, J = 7.5 Hz, 1H), 6.00 (s, 1H),
5.87–5.78 (m, 1H), 5.11 (dd, J = 24.7, 13.7
Hz, 2H), 3.58 (s, 3H), 3.32 (d, J = 17.6 Hz, 1H),
3.25 (d, J = 6.5 Hz, 2H), 2.57 (d, J = 17.6 Hz, 1H), 2.46 (s, 3H), 2.37–2.25 (m, 2H), 1.62–1.52
(m, 2H), 0.93 (dd, J = 14.1, 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ 207.4, 172.7, 170.1, 144.2,
137.9, 136.8, 135.7, 134.3, 131.7, 130, 127.7, 124.8, 117.3, 70.2,
62.4, 53.2, 48.9, 45.7, 25.6, 21.7, 13.9 IR (KBr): νmax 3020, 2927, 2852, 1731, 1706, 1435, 1215, 1160, 1023, 894, 750,
661 cm–1. MS (ESI): m/z 502 (M + Na)+; HRMS (ESI): m/z calcd for C27H29NO5SNa
(M + Na)+, 502.1659; found, 502.1637.

Methyl 8-(N-Allyl-4-methylphenylsulfonamido)-3-(3-((tert-butyldiphenylsilyl)oxy)propyl)-2-oxo-1,2,8,8a-tetrahydrocyclopenta[a]indene-8a-carboxylate (10g)
Colorless
liquid (59 mg, 64%). 1H NMR (500 MHz, CDCl3):
δ 7.85 (s, 1H), 7.79–7.76 (m, 1H), 7.65 (d, J = 3.4 Hz, 3H), 7.36 (tt, J = 5.2, 3.0 Hz, 11H),
7.29 (d, J = 7.5 Hz, 1H), 7.00 (d, J = 7.6 Hz, 1H), 6.00 (s, 1H), 5.37–5.28 (m, 1H), 5.11 (dd, J = 23.5, 13.8 Hz, 1H), 4.63 (d, J = 10.5
Hz, 1H), 4.37 (d, J = 17.0 Hz, 1H), 3.87 (d, J = 5.7 Hz, 1H), 3.73–3.68 (m, 2H), 3.52 (s, 3H),
2.63–2.56 (m, 3H), 2.55 (d, J = 6.1 Hz, 1H),
2.49 (s, 3H), 1.79–1.70 (m, 2H), 1.09 (s, 9H). 13C NMR (126 MHz, CDCl3): δ 207.2, 172.7, 170.3, 144.1,
144, 143.9, 142.4, 137.7, 137.4, 135.8, 135.7, 135.6, 135.4, 134.3,
133.8, 133.7, 131.7, 131.1, 130.1, 130, 129.8, 129.67, 129.1, 127.7,
127.6, 127.3, 125.1, 117.3, 116.7, 70.3, 65.9, 63.2, 63.1, 62.4, 62.1,
53.2, 53.1, 51.9, 48.9, 47.9, 45.8, 42.9, 31.2, 31.1, 29.7, 26.9,
21.7, 20.3, 20.1, 19.3. IR (KBr): νmax 3019, 2928,
2856, 1707, 1428, 1215, 1089, 931, 747, 663 cm–1. MS (ESI): m/z 756 (M + Na)+; HRMS (ESI): m/z calcd
for C43H48NO6SSi (M + H)+, 734.2972; found, 734.2976.

Methyl 8-((N-Allyl-4-methylphenyl)sulfonamido)-2-oxo-2,8-dihydrocyclopenta[a]indene-8a(1H)-carboxylate (10h)
White solid (99 mg, 81%). mp 145–147 °C. 1H NMR (500 MHz, CDCl3): δ 7.84 (d, J = 8.2 Hz, 2H), 7.61–7.57 (m, 1H), 7.45–7.37
(m, 4H), 7.04 (d, J = 6.2 Hz, 1H), 6.27 (s, 1H),
6.03 (s, 1H), 5.39–5.29 (m, 1H), 4.67 (d, J = 10.0 Hz, 1H), 4.45 (d, J = 17.1 Hz, 1H), 3.61
(s, 3H), 3.35–3.21 (m, 2H), 2.61–2.45 (m, 5H). 13C NMR (126 MHz, CDCl3): δ 207.1, 178.1,
172.1, 144.7, 143.9, 137.6, 134.8, 134.1, 132.7, 130.2, 130.1, 127.6,
127.3, 124.7, 123.6, 117.6, 64.4, 62.5, 53.5, 47.9, 43.9, 21.7. IR
(KBr): νmax 3020, 2954, 1709, 1625, 1434, 1341, 1215,
1159, 1030, 896, 815, 744, 660 cm–1. MS (ESI): m/z 460 (M + Na)+; HRMS (ESI): m/z calcd for C24H24NO5S (M + H)+, 438.1370; found, 438.1389.

Methyl 8-(N-((tert-Butyldimethylsilyl)oxy)-4-methylphenylsulfonamido)-2-oxo-3-phenyl-1,2,8,8a-tetrahydrocyclopenta[a]indene-8a-carboxylate (10i)
Pale
yellow solid (75 mg, 58%). mp 195–197 °C; 1H NMR (400 MHz, CDCl3): δ 7.75–7.70 (m, 2H),
7.48 (d, J = 7.8 Hz, 1H), 7.25–7.20 (m, 7H),
7.14–7.08 (m, 2H), 7.02–6.97 (m, 1H), 4.94 (s, 1H),
3.49 (s, 3H), 3.34 (d, J = 17.3 Hz, 1H), 2.53 (d, J = 17.3 Hz, 1H), 2.28 (s, 3H), 0.78 (s, 9H), 0.00 (s, 3H),
−0.29 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 204.9, 170.4, 169.9, 145.3, 142.6, 136.1, 133.7, 131.6,
130.9, 130.1, 129.9, 129.7, 129.4, 129.1, 128.9, 128.3, 123.4, 72.3,
64.7, 53.1, 48.4, 26.3, 21.8, 18.8, −4.1, −4.5. IR (KBr):
νmax 3054, 2930, 1710, 1365, 1171, 1044, 812, 669.
MS (ESI): m/z 604 (M + H)+; HRMS (ESI): m/z calcd for C33H38NO6SSi (M + H)+, 604.2189;
found, 604.2205.

Methyl 8-((N-Benzyl-4-methylphenyl)sulfonamido)-2-oxo-3-phenyl-2,8-dihydro-cyclopenta[a]indene-8a(1H)-carboxylate (10j)
White solid (107 mg, 79%). mp 194–196 °C. 1H NMR (400 MHz, CDCl3): δ 7.77 (d, J = 8.3 Hz, 2H), 7.66 (d, J = 7.0 Hz, 1H),
7.50–7.38 (m, 5H), 7.34–7.27 (m, 6H), 7.25–7.15
(m, 3H), 6.41 (d, J = 7.4 Hz, 1H), 5.76 (s, 1H),
4.74 (dd, J = 40.8, 17.5 Hz, 2H), 3.69–3.59
(m, 1H), 3.02 (d, J = 17.6 Hz, 1H), 2.91 (s, 3H),
2.45 (s, 3H). 13C NMR (126 MHz, CDCl3): δ
204.7, 170.1, 167.7, 144.2, 138.8, 136.4, 134.5, 131.9, 128.9, 128.3,
128.2, 126.7, 126.2, 124.7, 123.8, 69.9, 66.6, 52.7, 49.7, 45.2, 21.6.
IR (KBr): νmax 3025, 2952, 1707, 1599, 1344, 1161,
1026, 758, 662 cm–1. MS (ESI): m/z 586 (M + Na)+; HRMS (ESI): m/z calcd for C34H29NO5S (M + Na)+, 564.1839; found, 564.1864.

Methyl 2-(Hydroxy(2-(phenylethynyl)pyridin-3-yl)methyl)acrylate
(11)
Brown liquid (800 mg, 68%). 1H NMR (500 MHz, CDCl3): δ 8.57 (dd, J = 4.8, 1.7 Hz, 1H), 7.94 (dd, J = 7.9, 1.5 Hz,
1H), 7.58–7.53 (m, 2H), 7.41–7.33 (m, 3H), 7.31 (dt, J = 15.9, 7.9 Hz, 1H), 6.37 (s, 1H), 6.14 (d, J = 5.0 Hz, 1H), 5.70 (s, 1H), 3.76 (s, 3H), 3.46 (d, J = 5.3 Hz, 1H). 13C NMR (126 MHz, CDCl3): δ
166.9, 149.2, 141.5, 140.6, 138.9, 134.6, 131.9, 129.2, 128.5, 127.5,
123.1, 122.1, 94.3, 86.5, 69.9, 52.2 IR (KBr): νmax 3301, 2925, 2220, 1720, 1434, 1141, 757, 615. MS (ESI): m/z 294 (M + H)+; HRMS (ESI): m/z calcd for C18H16NO3 (M + H)+, 294.1130; found, 294.1137.

Methyl 2-(((tert-Butoxycarbonyl)oxy)(2-(phenylethynyl)pyridin-3-yl)methyl)acrylate
(12)
Brown liquid (922 mg, 86%). 1H NMR (400 MHz, CDCl3): δ 8.59 (dd, J = 4.8, 1.7 Hz, 1H), 7.74 (dd, J = 7.9, 1.4 Hz,
1H), 7.67–7.58 (m, 2H), 7.44–7.35 (m, 2H), 7.27 (q, J = 4.7 Hz, 2H), 7.07 (s, 1H), 6.53 (s, 1H), 5.83 (d, J = 0.7 Hz, 1H), 3.71 (s, 3H), 1.45 (s, 9H). 13C NMR (101 MHz, CDCl3): δ 165.1, 152.1, 149.7, 142.7,
137.9, 135.4, 134.7, 132.2, 129.2, 128.3, 128.2, 122.7, 122.1, 94.6,
86.2, 83.2, 72.9, 52.2, 27.7. IR (KBr): νmax 2929,
1747, 1434, 1275, 1158, 758, 693 = MS (ESI): m/z 394(M + H)+; HRMS (ESI): m/z calcd for C23H24NO5 (M + H)+, 394.1654; found, 394.1653.

Methyl 2-((4-Methylphenylsulfonamido)(2-(phenylethynyl)pyridin-3-yl)methyl)acrylate
(13)
Yellow liquid (89 mg, 79%). 1H NMR (500 MHz, CDCl3): δ 8.43 (dd, J = 4.7, 1.5 Hz, 1H), 7.72 (dd, J = 8.0, 1.4 Hz,
1H), 7.64 (d, J = 8.3 Hz, 2H), 7.61–7.56 (m,
2H), 7.44–7.38 (m, 3H), 7.13–7.07 (m, 3H), 6.26 (s,
1H), 6.20 (d, J = 8.9 Hz, 1H), 5.91 (d, J = 8.9 Hz, 1H), 5.88 (s, 1H), 3.61 (s, 3H), 2.30 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 165.7, 149.1, 143.5, 141.4,
137.4, 137.1, 136.2, 135.2, 132.1, 129.5, 129.4, 129.1, 128.6, 127.2,
122.7, 121.8, 94.7, 86.6, 56.4, 52.2, 21.4. IR = 3028, 2923, 2221,
1722, 1157, 1067, 755, 665. MS (ESI): m/z 447 (M + H)+; HRMS (ESI): m/z calcd for C25H22N2O4S (M + H)+, 447.1379; found, 447.1352.

Methyl 5-(4-Methylphenylsulfonamido)-7-oxo-8-phenyl-5,5a,6,7-tetrahydropentaleno[1,2-b]pyridine-5a-carboxylate (14)
Pale
yellow solid (77 mg, 82%). 206–208 °C. 1H NMR
(400 MHz, CDCl3): δ 8.59 (d, J =
4.7 Hz, 1H), 8.13–8.02 (m, 2H), 7.82 (d, J = 8.2 Hz, 2H), 7.71 (d, J = 7.8 Hz, 1H), 7.49–7.31
(m, 6H), 6.52 (d, J = 10.6 Hz, 1H), 4.94 (d, J = 10.6 Hz, 1H), 3.60 (s, 3H), 2.67 (d, J = 17.2 Hz, 1H), 2.51–2.47 (m, 3H). 13C NMR (101
MHz, CDCl3): δ 205.1, 172.2, 163.8, 152.1, 150.7,
144.3, 141.3, 137.7, 136.6, 131.8, 130.6, 130.1, 129.7, 129.1, 127.9,
127.1, 125.8, 65.4, 61.6, 53.5, 46.2, 21.7. IR (KBr): νmax 2925, 1712, 1598, 1405, 1262, 1161, 1083, 760. MS (ESI): m/z 474 (M + H)+; HRMS (ESI): m/z calcd for C26H22N2O5SNa (M + Na)+, 497.1528; found,
497.1539.

8-Hydroxy-2-oxo-3-phenyl-1,2,8,8a-tetrahydrocyclopenta[a]indene-8a-carbonitrile (16)
Pale
yellow solid (54 mg, 48%); mp 204–206 °C; 1H NMR (400 MHz, CDCl3): δ 7.74 (d, J = 7.8 Hz, 1H), 7.60 (dt, J = 14.8, 7.2 Hz, 2H),
7.54–7.42 (m, 5H), 7.38 (t, J = 7.2 Hz, 1H),
5.24 (d, J = 9.7 Hz, 1H), 3.28 (d, J = 17.9 Hz, 1H), 3.22 (d, J = 9.9 Hz, 1H), 3.09
(d, J = 17.9 Hz, 1H). 13C NMR (101 MHz,
CDCl3): δ 202.3, 164.0, 146.3, 136.0, 133.4, 132.5,
129.9, 129.5, 129.3, 129.2, 128.6, 125.2, 125.0, 119.2, 79.5, 57.7,
44.5. IR (KBr): νmax 3426, 3207, 2901, 2245, 1709,
1346, 1150, 757, 701. MS (ESI): m/z 288 (M + H)+; HRMS (ESI): m/z calcd for C19H14NO2 (M
+ H)+, 288.1025; found, 288.1031

(8S,8aR)-8-Hydroxy-3-phenyl-8,8a-dihydrocyclopenta[a]inden-2(1H)-one (17)
Pale
Yellow solid (35 mg, 34%). mp 173–175 °C. 1H NMR (400 MHz, CDCl3): δ 7.62 (d, J = 7.7 Hz, 1H), 7.51 (d, J = 7.0 Hz, 1H), 7.47–7.36
(m, 5H), 7.34–7.29 (m, 1H), 7.23 (t, J = 7.5
Hz, 1H), 5.00 (t, J = 6.5 Hz, 1H), 3.48 (td, J = 6.6, 4.6 Hz, 1H), 2.95 (dd, J = 17.7,
6.8 Hz, 1H), 2.66 (dd, J = 17.7, 4.5 Hz, 1H), 2.39
(d, J = 7.3 Hz, 1H). 13C NMR (126 MHz,
CDCl3): δ 205.8, 169.7, 148.6, 133.2, 132.9, 131.3,
130.0, 128.2, 127.7, 127.4, 123.8, 123.1, 77.2, 55.3, 39.6, 0.02.
IR (KBr): νmax 3456, 2924, 1711, 1639, 1350, 1120,
705 cm–1. MS (ESI): m/z 263 (M + H)+; HRMS (ESI): m/z calcd for C18H15O2 (M
+ H)+, 263.1072; found, 263.1077.

Supporting Information Available
The Supporting Information is
available free of charge on the ACS Publications website at DOI: 10.1021/acsomega.8b02111.Copies of 1H and 13C NMR spectra
of all new compounds and X-ray analysis data for 6a, 6b, 10e, and 16 (PDF)



Supplementary Material
ao8b02111_si_001.pdf

 The authors
declare no competing financial interest.

Acknowledgments
C.R.R. thanks the Science and Engineering
Research
Board, New Delhi, for funding the project (EMR/2016/006253). K.W.
thanks the Council of Scientific and Industrial Research (CSIR), New
Delhi, for a research fellowship (IICT/Pubs./2018/251).
==== Refs
References
For representative reviews on MBH-reaction:

a Baylis A. B. ; Hillman M. E. D.   German Patent 2155113 , 1972 ; Chem. Abstr. 1972 , 77 , 34174q .b Hillman M. E. D. ; Baylis A. B.   U.S. Patent 3,743,669 , 1973 .c Basavaiah D. ; Rao A. J. ; Satyanarayana T. 
Recent Advances in the Baylis–Hillman Reaction
and Applications . Chem. Rev. 
2003 , 103 , 811 –892 . 10.1021/cr010043d .12630854  d Declerck V. ; Martinez J. ; Lamaty F. 
aza-Baylis–Hillman Reaction . Chem. Rev. 
2009 , 109 , 1 –48 . 10.1021/cr068057c .19140772  e Basavaiah D. ; Reddy B. S. ; Badsara S. S. 
Recent Contributions
from the Baylis–Hillman Reaction to Organic Chemistry . Chem. Rev. 
2010 , 110 , 5447 –5674 . 10.1021/cr900291g .20735052  f Basavaiah D. ; Veeraraghavaiah G. 
The Baylis-Hillman reaction: a novel
concept for creativity in chemistry . Chem. Soc.
Rev. 
2012 , 41 , 68 –78 . 10.1039/c1cs15174f .21894342  g Wei Y. ; Shi M. 
Recent Advances in Organocatalytic
Asymmetric Morita–Baylis–Hillman/aza-Morita–Baylis–Hillman Reactions . Chem. Rev. 
2013 , 113 , 6659 –6690 . 10.1021/cr300192h .23679920  h Zhong N.-J. ; Wang Y.-Z. ; Cheng L. ; Dong W. ; Liu L. 
Recent Advances in the Annulation of Morita–Baylis–Hillman
Adducts . Org. Biomol. Chem. 
2018 , 16 , 5214 –5227 . 10.1039/c8ob00929e .29964282 
For recent reviews on MBH reaction involved
in the synthesis of natural products:

a Wang F.-J. ; Wei Y. ; Shi M.  Application of Morita–Baylis–Hillman
Reaction for the Synthesis of Natural Products ; RSC Publishing , 2011 ; pp 485 –551 .b Bhowmik S. ; Batra S. 
Applications of Morita-Baylis-Hillman
Reaction to the Synthesis of Natural Products and Drug Molecules . Curr. Org. Chem. 
2014 , 18 , 3078 –3119 . 10.2174/1385272819666141125003114 .
For synthetic methods on intramolecular Pauson-Khand
reaction of MBH adducts:

a Ishikawa S. ; Noguchi F. ; Uno H. ; Kamimura A. 
Intramolecular Pauson-Khand reaction of optically active
aza-Baylis-Hillman adducts . Tetrahedron Lett. 
2010 , 51 , 2329 –2331 . 10.1016/j.tetlet.2010.02.115 . b Reddy C. R. ; Kumaraswamy P. ; Singarapu K. 
Sequential
Allylic Substitution/Pauson– Khand Reaction: A Strategy to
Bicyclic Fused Cyclopentenones from MBH-Acetates of Acetylenic Aldehydes . J. Org. Chem. 
2014 , 79 , 7880 –7888 . 10.1021/jo500962d .25105763 
For synthetic methods on enyne-assisted annulations:

a Reddy C. R. ; Panda S. A. ; Ramaraju A. 
Oxidative Aza-Annulation
of Enynyl Azides to 2-Keto/Formyl-1H-pyrroles . J. Org. Chem. 
2017 , 82 , 944 –949 . 10.1021/acs.joc.6b02468 .28029044  b Reddy C. R. ; Ranjan R. ; Prajapti S. K. ; Warudikar K. 
One-Pot Consecutive
Sulfonamidation/ipso-Cyclization Strategy for the
Construction of Azaspirocyclohexadienones . J.
Org. Chem. 
2017 , 82 , 6932 –6939 . 10.1021/acs.joc.7b01285 .28621132  c Reddy C. R. ; Prajapti S. K. ; Ranjan R. 
Cu(I)-Catalyzed Aminative
Aza-Annulation of Enynyl Azide using N-Fluorobenzenesulfonimide: Synthesis
of 5-Aminonicotinates . Org. Lett. 
2018 , 20 , 3128 –3131 . 10.1021/acs.orglett.8b01228 .29708757 
For synthetic methods on
2-alkynyl benzaldehyde:

a Ko S. H. ; Lee K.-J. 
Synthesis of 5H-1,2,3-Triazolo[4,3-a][2]benzazepines
from the Baylis-Hillman Adducts of 2-Alkynyl benzaldehydes . J. Heterocycl. Chem. 
2004 , 41 , 613 –616 . 10.1002/jhet.5570410422 . b Ji S.-H. ; Hong W. P. ; Ko S. H. ; Lee K.-J. 
The Dipolar
Route to Naphtho[2,1-c]isoxazoles from the Baylis-Hillman Adducts
of 2-Alkynylbenzaldehydes . J. Heterocycl. Chem. 
2006 , 43 , 799 –801 . 10.1002/jhet.5570430344 . c Batchu H. ; Bhattacharyya S. ; Batra S. 
Iodine-Mediated Intramolecular Electrophilic
Aromatic Cyclization in Allylamines: A General Route to Synthesis
of Quinolines, Pyrazolo[4,3-b]pyridines, and Thieno[3,2-b]pyridines . Org. Lett. 
2012 , 14 , 6330 –6333 . 10.1021/ol303109m .23230893  d Deng G.-B. ; Wang Z.-Q. ; Xia J.-D. ; Qian P.-C. ; Song R.-J. ; Hu M. ; Gong L.-B. ; Li J.-H. 
Tandem
Cyclizations of 1,6-Enynes with Arylsulfonyl Chlorides by Using Visible-Light
Photoredox Catalysis . Angew. Chem., Int. Ed. 
2013 , 52 , 1535 –1538 . 10.1002/anie.201208380 . e Janreddy D. ; Kavala V. ; Kotipalli T. ; Rajawinslin R. R. ; Kuo C.-W. ; Huang W.-C. ; Yao C.-F. 
Molecular iodine-mediated
reaction of 2-(2-phenylethynyl)-Morita-Baylis-Hillman adducts: an
easy route to naphthyl ketones and iodo-substituted isochromenes . Org. Biomol. Chem. 
2014 , 12 , 8247 –8256 . 10.1039/c4ob00938j .25203199  f Wang Z.-Q. ; Xu K. ; Zhang X. ; Li T. ; Zheng S.-L. ; Yu L.-T. ; Mao W.-T. ; Chen C.-Z. ; Wang L.-Y. 
A New Route to Naphthyl Ketones via Copper-Mediated Intramolecular Aerobic Oxidative Cyclization of
Alkynes and Sulfonylcrotonates . RSC Adv. 
2016 , 6 , 103919 –103922 . 10.1039/c6ra23244b . g Xuan J. ; Gonzalez-Abradelo D. ; Strassert C. A. ; Daniliuc C.-G. ; Studer A. 
Radical Cascade
Cyclization: Reaction of 1,6-Enynes with Aryl Radicals by Electron
Catalysis . Eur. J. Org. Chem. 
2016 , 2016 , 4961 –4964 . 10.1002/ejoc.201601033 .
a Ohyama M. ; Tanaka T. ; Iinuma M. 
Five Resveratrol
oligomers
from roots Of Sophora Leachiana . Phytochemistry 
1995 , 38 , 733 –740 . 10.1016/0031-9422(94)00722-6 . b Baderschneider B. ; Winterhalter P. 
Isolation
and Characterization of Novel Stilbene Derivatives from Riesling Wine . J. Agric. Food Chem. 
2000 , 48 , 2681 –2686 . 10.1021/jf991348k .11032479  c Xi Z. ; Hwang G.-S. ; Goldberg I. H. ; Harris J. L. ; Pennington W. T. ; Fouad F. S. ; Qabaja G. ; Wright J. M. ; Jones G. B. 
Targeting DNA Bulged Microenvironments
with Synthetic Agents . Chem. Biol. 
2002 , 9 , 925 –931 . 10.1016/s1074-5521(02)00188-6 .12204692 d Meng D.  Process for the
Synthesis of Estrogen Receptor Modulators . U.S. Patent US680,078,5B1 , 2004 . e Gaikwad N. W. ; Hwang G.-S. ; Goldberg I. H. 
Synthesis
and NMR Binding Study of a Chiral Spirocyclic Helical Analogue of
a Natural DNA Bulge Binder . Org. Lett. 
2004 , 6 , 4833 –4836 . 10.1021/ol048152c .15606078  f Oh D.-C. ; Williams P. G. ; Kauffman C. A. ; Jensen P. R. ; Fenical W. 
Cyanosporasides
A and B, Chloro- and Cyano-cyclopenta[a]indene Glycosides from the
Marine Actinomycete ″Salinispora pacifica″ . Org. Lett. 
2006 , 8 , 1021 –1024 . 10.1021/ol052686b .16524258  g Xiao Z. ; Kappen L. S. ; Goldberg I. H. 
Development of new
simple molecular probes of DNA bulged structures . Bioorg. Med. Chem. Lett. 
2006 , 16 , 2895 –2899 . 10.1016/j.bmcl.2006.03.006 .16546380  h Snyder S. A. ; Zografos A. L. ; Lin Y. 
Total Synthesis of Resveratrol-Based Natural Products: A Chemoselective
Solution . Angew. Chem., Int. Ed. 
2007 , 46 , 8186 –8191 . 10.1002/anie.200703333 .
Heinz C. ; Cramer N. 
Synthesis of Fijiolide A via an Atropselective
Paracyclophane
Formation . J. Am. Chem. Soc. 
2015 , 137 , 11278 –11281 . 10.1021/jacs.5b07964 .26301726 
a Suzuki K. ; Urabe H. ; Sato F. 
A Novel Tandem Cyclization
of 2,7- or 2,8-Bis-Unsaturated Esters Mediated by (η2-Propene)TiX2(X
= Cl or O-i-Pr). A Facile Construction of Bicyclo[3.3.0]octane, -[4.3.0]nonane,
and -[3.1.0]hexane Skeletons . J. Am. Chem. Soc. 
1996 , 118 , 8729 –8730 . 10.1021/ja961928n . b Urabe H. ; Suzuki K. ; Sato F. 
Intramolecular Cyclization of 2,7-
or 2,8-Bis-unsaturated Esters Mediated by (η2-Propene)Ti(O-i-Pr)2.
Facile Construction of Mono- and Bicyclic Skeletons with Stereoselective
Introduction of a Side Chain. A Synthesis ofd-Sabinene . J. Am. Chem. Soc. 
1997 , 119 , 10014 –10027 . 10.1021/ja9716160 . c Dölling W. ; Vogt A. ; Baumeister U. ; Hartung H. 
Synthesis of 3,7-Disubstituted 9-Thiatricyclo[3.3.1.03,7]nonane-1,5-dithiol
Derivatives and Crystal Structure of Tetramethyl 3(4aH)-Oxo-1,4-dihydrophenanthro[9,10-a]pentalene-1,2,4,4a-tetracarboxylate . Eur. J. Org. Chem. 
1998 , 1998 , 2647 –2650 . 10.1002/(sici)1099-0690(199811)1998:11<2647::aid-ejoc2647>3.0.co;2-v . d Yadav V. K. ; Sriramurthy V. 
Formal[3+2] Addition of Acceptor-Substituted
Cyclopropylmethylsilanes with Aryl Acetylenes . Angew. Chem., Int. Ed. 
2004 , 43 , 2669 –2671 . 10.1002/anie.200453823 . e Yu C. ; Chen B. ; Zhou T. ; Tian Q. ; Zhang G. 
Gold(I)-Catalyzed Tandem Transformation
with Diynes: Rapid Access to Linear Cyclopentenone-Fused Polycyclic
Molecules . Angew. Chem., Int. Ed. 
2015 , 54 , 10903 –10907 . 10.1002/anie.201503599 . f Dobrowolski M. A. ; Roszkowski P. ; Struga M. ; Szulczyk D. 
The unexpected product
of Diels-Alder reaction between ″indanocyclon″ and maleimide . J. Mol. Struct. 
2017 , 1130 , 573 –578 . 10.1016/j.molstruc.2016.10.067 .
a Cragoe E. J. Jr.; Woltersdorf O. W. Jr.; Gould N. P. ; Pietruszkiewicz A. M. ; Ziegler C. ; Sakurai Y. ; Stokker G. E. ; Anderson P. S. ; Bourke R. S. 
Agents for the treatment of brain edema. 2. [(2,3,9,9a-Tetrahydro-3-oxo-9a-substituted-1H-fluoren-7-yl)oxy]alkanoic
acids and some of their analogs . J. Med. Chem. 
1986 , 29 , 825 –841 . 10.1021/jm00155a038 .3701792  b Meng D. ; Parker D. L. Jr.
Synthesis of α,β-disubstituted
cycloalkenones through a sequence of olefin metathesis and oxidative
rearrangement . Tetrahedron Lett. 
2002 , 43 , 9035 –9038 . 10.1016/s0040-4039(02)02307-9 . c Ohno H. ; Wakayama R. ; Maeda S.-i. ; Iwasaki H. ; Okumura M. ; Iwata C. ; Mikamiyama H. ; Tanaka T. 
Radical Cyclization by Ipso Substitution of the Methoxy
Group: Considerable Effect of HMPA on Samarium-Mediated Cyclization . J. Org. Chem. 
2003 , 68 , 5909 –5916 . 10.1021/jo0343174 .12868925  d Dubé P. ; Toste F. D. 
Synthesis
of Indenyl Ethers by Gold(I)-Catalyzed Intramolecular Carboalkoxylation
of Alkynes . J. Am. Chem. Soc. 
2006 , 128 , 12062 –12063 . 10.1021/ja064209+ .16967944  e Kim K. H. ; Lee H. S. ; Kim S. H. ; Kim S. H. ; Kim J. N. 
Construction
of a Tetracyclic Butterfly-Like Scaffold: Palladium-Catalyzed Heck/Arylation
Cascade . Chem.—Eur. J. 
2010 , 16 , 2375 –2380 . 10.1002/chem.200903029 .20108282  f Peixoto P. A. ; Cormier M. ; Ekosso Epane J. ; Jean A. ; Maddaluno J. ; De Paolis M. 
Metal-free aerobic C-H oxidation of cyclic enones . Org. Chem. Front. 
2014 , 1 , 748 –754 . 10.1039/c4qo00125g . g Geibel I. ; Kahrs C. ; Christoffers J. 
Formation
of Bicyclic Cyclopentenone Derivatives by Robinson-Type Annulation
of Cyclic β-Oxoesters Containing a 1,4-Diketone Moiety . Synthesis 
2017 , 49 , 3874 –3884 . 10.1055/s-0036-1590812 .
a Khand I. U. ; Pauson P. L. 
An Organometallic
Route to 2,7-Dihydrothiepin-1,1-dioxides . Heterocycles 
1978 , 11 , 59 –67 . 10.3987/s(n)-1978-01-0059 .For selected reviews on Pauson-Khand reaction:

 b Brummond K. M. ; Kent J. L. 
Recent Advances in the Pauson-Khand
Reaction and Related [2+2+1] Cycloadditions . Tetrahedron 
2000 , 56 , 3263 –3283 . 10.1016/s0040-4020(00)00148-4 . c Shibata T. 
Recent Advances in the Catalytic Pauson-Khand-Type
Reaction . Adv. Synth. Catal. 
2006 , 348 , 2328 –2336 . 10.1002/adsc.200600328 .
For selected references, see:

a Sugihara T. ; Yamaguchi M. 
The Pauson–Khand Reaction
Catalyzed by the Methylidynetricobalt Nonacarbonyl Cluster . J. Am. Chem. Soc. 
1998 , 120 , 10782 –10783 . 10.1021/ja982635s . b Adrio J. ; Carretero J. C. 
Thetert-Butylsulfinyl
Group as a Highly Efficient Chiral Auxiliary in Asymmetric Pauson–Khand
Reactions . J. Am. Chem. Soc. 
1999 , 121 , 7411 –7412 . 10.1021/ja990546p . c Jeong N. ; Sung B. K. ; Choi Y. K. 
Rhodium(I)-Catalyzed Asymmetric Intramolecular
Pauson–Khand-Type Reaction . J. Am. Chem.
Soc. 
2000 , 122 , 6771 –6772 . 10.1021/ja0007049 . d Ruano J. L. G. ; Torrente E. ; Parra A. ; Alemán J. ; Martín-Castro A. M. 
Asymmetric Intramolecular Pauson–Khand
Reaction Mediated by a Remote Sulfenyl or Sulfinyl Group . J. Org. Chem. 
2012 , 77 , 6583 –6599 . 10.1021/jo3011039 .22804714  e Fustero S. ; Lázaro R. ; Aiguabella N. ; Riera A. ; Simón-Fuentes A. ; Barrio P. 
Asymmetric Allylation/Pauson-Khand Reaction: A Simple
Entry to Polycyclic Amines. Application to the Synthesis of Aminosteroid
Analogues . Org. Lett. 
2014 , 16 , 1224 –1227 . 10.1021/ol500142c .24506268 
a Iwasawa N. ; Matsuo T. 
Synthesis of polycyclic
compounds by the reaction of Co2(CO)6 complexed
1-[o-(1-Alkynyl)Phenyl]cyclopropanols . Chem. Lett. 
1997 , 26 , 341 –342 . 10.1246/cl.1997.341 . b Morimoto T. ; Fuji K. ; Tsutsumi K. ; Kakiuchi K. 
CO-Transfer
Carbonylation Reactions. A Catalytic Pauson–Khand-Type Reaction
of Enynes with Aldehydes as a Source of Carbon Monoxide . J. Am. Chem. Soc. 
2002 , 124 , 3806 –3807 . 10.1021/ja0126881 .11942798  c Fuji K. ; Morimoto T. ; Tsutsumi K. ; Kakiuchi K. 
Aqueous Catalytic Pauson-Khand-Type Reactions of Enynes
with Formaldehyde: Transfer Carbonylation Involving an Aqueous Decarbonylation
and a Micellar Carbonylation . Angew. Chem.,
Int. Ed. 
2003 , 42 , 2409 –2411 . 10.1002/anie.200351384 . d Datta S. ; Liu R.-S. 
Molybdenum-mediated cyclocarbonylation
of 1-ethynyl-2-allenylbenzenes to 1H-cyclopenta[a]inden-2-ones . Tetrahedron Lett. 
2005 , 46 , 7985 –7988 . 10.1016/j.tetlet.2005.09.068 . e Ikeda I. ; Morimoto T. ; Tsumagari T. ; Tanimoto H. ; Nishiyama Y. ; Kakiuchi K. 
Rh(I)-Catalyzed Cyclocarbo-nylation of enynes with
glyceraldehyde: An available carbonyl source derived from sugar alcohols . Synlett 
2012 , 23 , 393 –396 . 10.1055/s-0031-1290311 . f Mukai C. ; Arima K. ; Hirata S. ; Yasuda S. 
Synthesis
of a carbon analogue of Scytonemin . Chem. Pharm.
Bull. 
2015 , 63 , 273 –277 . 10.1248/cpb.c14-00838 .25832021  g Aburano D. ; Inagaki F. ; Tomonaga S. ; Mukai C. 
Synthesis
of a Core Carbon Framework of Cyanosporasides A and B . J. Org. Chem. 
2009 , 74 , 5590 –5594 . 10.1021/jo901141t .19558182

